Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP, Yang G, Hanzis C, Ioakimidis L, Verselis SJ, Fox EA, Xu L, Hunter ZR, Tseng H, Manning RJ, Patterson CJ, Sheehy P, Turnbull B. Treon SP, et al. Among authors: manning rj. Br J Haematol. 2011 Jul;154(2):223-8. doi: 10.1111/j.1365-2141.2011.08726.x. Epub 2011 May 12. Br J Haematol. 2011. PMID: 21564078 Free article.
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Leleu X, et al. Among authors: manning rj. Br J Haematol. 2009 Apr;145(1):59-63. doi: 10.1111/j.1365-2141.2009.07592.x. Epub 2009 Feb 6. Br J Haematol. 2009. PMID: 19220283 Free article.
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP. Ciccarelli BT, et al. Among authors: manning rj. Clin Lymphoma Myeloma. 2009 Mar;9(1):56-8. doi: 10.3816/CLM.2009.n.014. Clin Lymphoma Myeloma. 2009. PMID: 19362974
Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
Treon SP, Hanzis C, Manning RJ, Ioakimidis L, Patterson CJ, Hunter ZR, Sheehy P, Turnbull B. Treon SP, et al. Among authors: manning rj. Br J Haematol. 2011 Aug;154(3):357-62. doi: 10.1111/j.1365-2141.2011.08750.x. Epub 2011 May 25. Br J Haematol. 2011. PMID: 21615385 Free article.
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. Treon SP, et al. Among authors: manning rj. Br J Haematol. 2018 Feb;180(3):374-380. doi: 10.1111/bjh.15049. Epub 2017 Nov 27. Br J Haematol. 2018. PMID: 29181840 Free article.
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. Moreau AS, et al. Br J Haematol. 2008 Sep;142(5):775-85. doi: 10.1111/j.1365-2141.2008.07257.x. Epub 2008 Jun 3. Br J Haematol. 2008. PMID: 18537966 Free article.
79 results